How SEBs Are Changing the Canadian Healthcare Market

Posted by Matt Wills on Tue, Jan 17, 2017

Subsequent entry biologics (SEBs), or biosimilars, have been making a lot of news in Canada lately. While the discussion has been happening for years already, we’ve started to see how regulatory and payer decisions are shaping this new market. We’ve recently seen payers implement coverage inconsistently (such as the “limited use” code in Ontario, mandatory substitution for new starts in British Columbia and preferential listing in some private payers), regulatory bodies update indications (Inflectra now includes Crohn’s disease and ulcerative colitis), and new products launched (etanercept and insulin glargine).

Read More